|[March 07, 2013]
Cellectis and Stemgent Partner to Provide Custom Genome-engineered iPS Cells
CAMBRIDGE, Mass. --(Business Wire)--
bioresearch, a subsidiary of Cellectis Group (Alternext:
ALCLS), the genome engineering specialist, announced today a
collaboration agreement with Stemgent, Inc. to provide research services
that combines mRNA reprogramming technology and genome engineering.
The partnership marries Cellectis bioresearch's leadership in genome
engineering with Stemgent's expertise in cellular reprogramming.
Stemgent's proprietary mRNA reprogramming technology addresses the
challenges around deriving non-viral, non-integrating,
clinically-relevant induced pluripotent stem (iPS) cells for use in
regenerative medicine, drug discovery, and basic research. Traditional
reprogramming methods can lead to the integration of unwanted genetic
material into the host genome and therefore can be disruptive to the
reprogrammed cell's function.
Targeted genome engineering is a powerful technology that can be used to
elucidate the genetic basis of diseases and to evaluate drug candidates
through the generation of cell-based assays. Cellectis bioresearch's
TALEN™-based genome engineering technology enables the directed
introduction of disease-specific genetic mutations to mimic disease and
of reporter genes with fluorescent/luminescent tags to evaluate drug
candidate efficacy, specificity and toxicity. Together these two
powerful technologies pave the way for clinically-relevant applications
in regenerative medicine.
Cellectis Group CEO André Choulika said, "The collaboration between
Stemgent and Cellectis fits with our mission to enable scientists
worldwide with the tools to generate genome-engineered iPS cells for use
in their research and regeneraive medicine."
"Drug toxicity testing is an important part of early-stage drug
development, continued Ian Ratcliffe, Stemgent President and CEO. "The
challenge researchers face is that current models to test drugs are
often inadequate. With this partnership and the combined technologies,
we can introduce mutations into reprogrammed cells and differentiate
them into downstream lineages. Researchers can utilize these cells to
test how mutations, known and unknown, alter the biology of the cells
upon exposure to drugs."
Founded in France in 1999, the Cellectis Group is based on a highly
specific DNA engineering technology. Its application sectors are human
health, agriculture and bio-energies. Co-created by André Choulika, its
Chief Executive Officer, Cellectis is today one of the world leading
companies in the field of genome engineering. Cellectis is also focused
on pluripotent stem cells and technology for drug discovery research,
toxicity testing and regenerative medicine. Cellectis leverages a deep
experience in stem cell handling, scale-up and differentiation into
mature and functional human cells. The Group has a workforce of 230
employees working on 5 sites worldwide: Paris & Evry in France,
Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in
the United States. Cellectis achieved in 2011 €16M revenues and has
signed more than 80 industrial agreements with pharmaceutical
laboratories, agrochemical and biotechnology companies since its
inception. AFM, Dupont, BASF, Bayer, Total, Limagrain, Novo Nordisk… are
some of the Group's clients and partners. Since 2007, Cellectis has been
listed on NYSE-Euronext Alternext market (code: ALCLS) in Paris.
For more information, visit our website: www.cellectis.com.
Stemgent, Inc. is engaged in working alongside some of the world's
leading stem cell scientists in developing innovative technology and
application solutions for the advancement of stem cell research.
Stemgent's mission is to help simplify and support cellular
reprogramming by producing research tools being designed by leading stem
cell researchers worldwide. Stemgent's product offering includes:
reprogramming systems, media, small molecules, antibodies, customized
services, and training programs. In 2012, the company merged with
Asterand which provides well characterized human tissue specimens
through its XpressBank™ biorepository and its PhaseZERO™ human-tissue
custom services platform.
For more information, visit www.stemgent.com
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
[ Back To Technology News's Homepage ]